Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 26, 2017 08:30 ET | Source: TESARO, Inc.

TESARO Announces Approval of VARUBY® (Oral Rolapitant Tablets) by European Commission

VARUBY provides protection for delayed chemotherapy-induced nausea and vomiting (CINV) with a single dose as part of an antiemetic regimenUp to 50% of patients undergoing highly or moderately...
February 27, 2017 02:00 ET | Source: TESARO, Inc.

TESARO Receives Positive CHMP Opinion for VARUBY®

WALTHAM, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the European Medicines Agency’s (EMA) Committee for...
March 23, 2016 09:00 ET | Source: TESARO, Inc.

TESARO Announces Validation of Marketing Authorisation Application for Oral Rolapitant by the European Medicines Agency

WALTHAM, Mass., March 23, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the Marketing Authorisation Application (MAA) for...
March 14, 2016 08:05 ET | Source: TESARO, Inc.

TESARO Submits New Drug Application for Intravenous Rolapitant to the U.S. Food and Drug Administration

WALTHAM, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has submitted the New Drug Application (NDA)...